Want to see LKFT full AI Analyst Report?
LKFT Stock Chart & Stats
$29.28
-$0.67(-2.33%)
At close: 4:00 PM EST
$29.28
-$0.67(-2.33%)
Day’s Range― - ―
52-Week Range$26.42 - $37.78
Previous CloseN/A
VolumeN/A
Average Volume (3M)110.39K
Market Cap
$1.96B
Enterprise Value-$1.36K
Total Cash (Recent Filing)$2.98B
Total Debt (Recent Filing)$6.43M
Price to Earnings (P/E)3.5
Beta0.74
Next Earnings
Aug 10, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.42
Shares Outstanding65,897,070
10 Day Avg. Volume99,472
30 Day Avg. Volume110,389
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.57
Price to Sales (P/S)1.65
P/FCF Ratio-6.76
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$29.00Price Target Upside-0.96% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-3.27
Revenue Forecast (FY)$28.40M
Bulls Say, Bears Say
Bulls Say
Strong Cash And InvestmentsA nearly EUR 3.0bn cash/investment base gives the company durable financial flexibility to fund R&D, co‑fund the Ouro transaction, pursue BD opportunities, and absorb near‑term losses without immediate refinancing, materially reducing short‑term solvency risk.
Strategic Gilead/Ouro Partnership And Asset AddCo‑development rights to gamgertamig and additional preclinical assets provide a durable pipeline shift into T‑cell engager autoimmune therapies, plus tiered royalties and shared development economics that create longer‑term revenue and value capture pathways.
Governance Refresh And Capital FlexibilityA refreshed board/management and approved buyback program improve strategic oversight and capital allocation optionality. Strong governance and new mandates support disciplined dealmaking and align incentives, aiding execution of the strategic transformation over coming quarters.
Bears Say
Persistent Negative Cash GenerationSustained negative operating and free cash flow forces reliance on the balance sheet and external funding for operations and development. Even with a strong cash buffer, continued cash burn elevates dilution or asset‑sale risk if clinical or transaction timelines slip.
Large Near‑term Cash Outflows (Ouro & Wind‑down)Material one‑time cash deployments will meaningfully reduce available liquidity in 2026 and concentrate execution risk on successful integration and development of gamgertamig; this limits optionality for additional BD unless milestones or dispositions occur.
Revenue Volatility And Low Recurring Product IncomeRevenue swings driven by deferred income recognition highlight a lack of stable commercial product sales. Dependence on collaboration accounting and transaction timing undermines predictable cash flow and increases reliance on sporadic milestone/upfront payments for reported income.
Lakefront Biotherapeutics News
LKFT FAQ
What was Lakefront Biotherapeutics’s price range in the past 12 months?
Lakefront Biotherapeutics lowest stock price was $26.42 and its highest was $37.78 in the past 12 months.
What is Lakefront Biotherapeutics’s market cap?
Lakefront Biotherapeutics’s market cap is $1.96B.
When is Lakefront Biotherapeutics’s upcoming earnings report date?
Lakefront Biotherapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 21 days.
How were Lakefront Biotherapeutics’s earnings last quarter?
Lakefront Biotherapeutics released its earnings results on May 06, 2026. The company reported $0.247 earnings per share for the quarter, beating the consensus estimate of -$0.944 by $1.191.
Is Lakefront Biotherapeutics overvalued?
According to Wall Street analysts Lakefront Biotherapeutics’s price is currently Overvalued.
Does Lakefront Biotherapeutics pay dividends?
Lakefront Biotherapeutics does not currently pay dividends.
What is Lakefront Biotherapeutics’s EPS estimate?
Lakefront Biotherapeutics’s EPS estimate is -0.82.
How many shares outstanding does Lakefront Biotherapeutics have?
Lakefront Biotherapeutics has 65,897,070 shares outstanding.
What happened to Lakefront Biotherapeutics’s price movement after its last earnings report?
Lakefront Biotherapeutics reported an EPS of $0.247 in its last earnings report, beating expectations of -$0.944. Following the earnings report the stock price went down -3.749%.
Which hedge fund is a major shareholder of Lakefront Biotherapeutics?
Currently, no hedge funds are holding shares in LKFT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lakefront Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$29.00 (-0.96% Downside)
$29.00 (-0.96% Downside)
Hedge Fund Trend
Decreased
By 32.0K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.37%
12-Months-Change
Fundamentals
Return on Equity
16.88%
Trailing 12-Months
Asset Growth
-10.56%
Trailing 12-Months
Company Description
Lakefront Biotherapeutics
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
LKFT Stock 12 Month Forecast
Average Price Target
$29.00
▼(-0.96% Downside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
―
Insiders
1.70% Mutual Funds
41.89% Other Institutional Investors
55.70% Public Companies and
Individual Investors